HomeCORT • NASDAQ
Corcept Therapeutics Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 181.89M | 34.33% |
Operating expense | 153.67M | 50.87% |
Net income | 30.75M | -1.94% |
Net profit margin | 16.90 | -27.03% |
Earnings per share | 0.26 | -7.14% |
EBITDA | 25.54M | -19.89% |
Effective tax rate | 3.80% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 383.33M | 4.10% |
Total assets | 840.55M | 35.24% |
Total liabilities | 160.96M | 40.20% |
Total equity | 679.59M | — |
Shares outstanding | 105.50M | — |
Price to book | 14.21 | — |
Return on assets | 7.77% | — |
Return on capital | 9.48% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 30.75M | -1.94% |
Cash from operations | 59.30M | 907.30% |
Cash from investing | -64.36M | -476.42% |
Cash from financing | -4.56M | -695.82% |
Net change in cash | -9.62M | -140.52% |
Free cash flow | 45.46M | 2,538.10% |
Previous close
$91.93
Day range
$83.44 - $90.50
Year range
$20.84 - $117.33
Market cap
8.89B USD
Avg Volume
1.83M
P/E ratio
67.72
Dividend yield
-
Primary exchange
NASDAQ
About
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
Founded
May 13, 1998
Headquarters
Website
Employees
500
